Publications by authors named "Sarah Parisi"

Claim this Profile
S
Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms.
Eleonora Ceneri, Alessia De Stefano, Irene Casalin, Carlo Finelli, Antonio Curti, Sarah Parisi

Adv Biol Regul· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of Cancer Stem Cells in Normal and Dysplastic/Leukemic Human Blood.
Alessia De Stefano, Alessandra Cappellini, Irene Casalin, Stefania Paolini, Sarah Parisi

Methods Mol Biol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression.
Irene Casalin, Alessia De Stefano, Eleonora Ceneri, Alessandra Cappellini, Carlo Finelli, Sarah Parisi

Adv Biol Regul· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study.
Giovanni Marconi, Anna Candoni, Roberta Di Nicola, Chiara Sartor, Sarah Parisi

Cancer Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.
Raffaella Meazza, Loredana Ruggeri, Fabio Guolo, Paola Minetto, Paolo Canevali, Sarah Parisi

Front Immunol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Sara Mongiorgi, Alessia De Stefano, Stefano Ratti, Valentina Indio, Annalisa Astolfi, Sarah Parisi

Clin Epigenetics· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.
Chiara Sartor, Mario Arpinati, Gabriella Chirumbolo, Luca Dozza, Gianluca Cristiano, Sarah Parisi

Hematol Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.
Cristina Papayannidis, Jacopo Nanni, Gianluca Cristiano, Giovanni Marconi, Chiara Sartor, Sarah Parisi

Eur J Haematol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the rationale for red cell transfusion in myelodysplastic syndrome patients: emerging data and future insights.
Carlo Finelli, Sarah Parisi, Stefania Paolini

Expert Rev Hematol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
Sarah Parisi, Loredana Ruggeri, Elisa Dan, Simonetta Rizzi, Barbara Sinigaglia

Front Immunol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia.
Federico Ravaioli, Giovanni Marconi, Giovanni Martinelli, Elton Dajti, Chiara Sartor, Sarah Parisi

Cancer Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia.
Simone Ragaini, Sarah Wagner, Giovanni Marconi, Sarah Parisi, Chiara Sartor

Blood Adv· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement.
Gianluca Cristiano, Jacopo Nanni, Chiara Sartor, Sarah Parisi, Giovanni Marconi

Acta Haematol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients.
Sarah Parisi, Carlo Finelli

J Blood Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
Cristina Papayannidis, Chiara Sartor, Alida Dominietto, Elisabetta Zappone, Mario Arpinati, Sarah Parisi

Hematol Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.
Giovanni Marconi, Stefano De Polo, Giovanni Martinelli, Jacopo Nanni, Luca Bertamini, Sarah Parisi

Leuk Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia.
Sarah Parisi, Carlo Finelli, Antonietta Fazio, Alessia De Stefano, Sara Mongiorgi

Int J Mol Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical impact of COVID-19 epidemic in the hematologic setting.
Carlo Finelli, Sarah Parisi

Adv Biol Regul· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.
Giovanni Marconi, Annalisa Talami, Maria Chiara Abbenante, Chiara Sartor, Sarah Parisi

Eur J Haematol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.
Matilde Y Follo, Andrea Pellagatti, Richard N Armstrong, Stefano Ratti, Sara Mongiorgi, Sarah Parisi

Leukemia· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute Myeloid Leukemia Mutations: Therapeutic Implications.
Cristina Papayannidis, Chiara Sartor, Giovanni Marconi, Maria Chiara Fontana, Jacopo Nanni, Sarah Parisi

Int J Mol Sci· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Giulia Corradi, Carmen Baldazzi, Darina Očadlíková, Giovanni Marconi, Sarah Parisi

Stem Cell Res Ther· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.
Andrea Ghelli Luserna Di Rorà, Neil Beeharry, Enrica Imbrogno, Anna Ferrari, Valentina Robustelli, Sarah Parisi

J Hematol Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach.
Alessandro Isidori, Federica Loscocco, Marilena Ciciarello, Giulia Corradi, Mariangela Lecciso, Sarah Parisi

Cancers (Basel)· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The More, The Better: "Do the Right Thing" For Natural Killer Immunotherapy in Acute Myeloid Leukemia.
Sarah Parisi, Mariangela Lecciso, Darina Ocadlikova, Valentina Salvestrini, Marilena Ciciarello

Front Immunol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis